News

Baricitinib is being co-developed by Eli Lilly and Company and Incyte under an exclusive global license and collaboration agreement signed in December 2009. It is intended to be taken orally

The improvement was observed in the 4mg/day dose arm, while the 2mg/day dose arm did not show a statistically significant difference from placebo. Both dasotraline arms were generally

Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV. The

The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has

The QIDP status provides for accelerated review of the New Drug Application (NDA) as well as a five-year period of market exclusivity for the indication, if approved. Currently,

According to information published on clinicaltrials.gov, the randomized, subject- and investigator-blinded study will enroll 60 obese adult patients with type 2 diabetes to assess the safety, pharmacokinetics and

The US Court of Appeals for the Federal Circuit has upheld the earlier district court's decision that a proposed generic equivalent from Teva Pharmaceutical Industries would infringe on

Merck paid $230m upfront for two clinical-stage DNA damage and repair candidates and two additional preclinical programs, of which the company will take full responsibility in development and commercialization. US-based

This global Phase 2a clinical trial is being conducted in approximately 150 ambulatory patients diagnosed with influenza A. Patients in the Phase 2a clinical trial will be randomized